I’m opening this Issue with a review of some of the alternative views I have heard since my last missive which, broadly, criticised conspiratorial theories and personal attacks that have taken hold in the wake of negative verdicts by both ICER and FDA’s Psychopharmacologic Drugs AdComm. In response to that piece, I have received various ‘You got it wrong this time, Josh!’, or ‘You missed…